dataesr/scientific-paragraphs-categorization huggingface dataset:
This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) Special Program Innovative Tools for Cancer Risk Assessment and early Diagnosis 5 × 1000 (No. 12162 to LR) and by Fondi 5 × 1000 Ministero della Salute 2015 (D/17/1VH to VH) and by the Italian Ministry of Health (RF-2016-02363001 to G. P. ) and by Horizon 2020 PRECIOUS Project, Grant Agreement no. 686089 to LR. We would like to thank the patients and participating study team for making this study happen. DB, DR, and DC work has been supported by Sidra Precision Medicine Program internal funds (SDR400019, SDR400027, and SDR400123). Open Access funding provided by the Qatar National Library. AVA I L A B I L I T Y O F D ATA A N D M AT E R I A L Raw expression and normalized data matrix have been deposited at NCBI's Gene Expression Omnibus database (http://www.
Kavanaugh et al. [5]  confirmed that improvement in both joint and skin manifestations is necessary to optimise improvement in HRQoL. For this reason, a combination of two validated outcome measures (≥ 50% improvement in ACR criteria [ACR50] and 100% improvement in Psoriasis Area Severity Index score [PASI100]) was defined as the primary endpoint in the phase IIIb/IV 52-week head-tohead SPIRIT-H2H trial (NCT03151551) of the interleukin (IL)-17A antagonist ixekizumab and the tumour necrosis factor (TNF) inhibitor adalimumab  [6]. Ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A; it is approved in the USA and European Union for the treatment of moderate-to-severe plaque psoriasis (PsO) in adults and children aged ≥ 6 years and PsA and axial spondyloarthritis in adults  [7, 8].
SPIRIT-H2H design The design of SPIRIT-H2H (NCT03151551) has already been presented  [6]  and is therefore described only briefly here. SPIRIT-H2H was a 52-week, multicentre, randomised, open-label, assessor-blinded, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in adult patients fulfilling Classification for Psoriatic Arthritis criteria for active PsA (tender joint count ≥ 3/68, swollen joint count ≥ 3/66) and with active PsO (body surface area [BSA] involvement of ≥ 3%) who had an inadequate response to ≥ 1 csDMARDs and were naïve to bDMARDs  [6]. Patients were randomised (1:1 and stratified by the presence of moderate-to-severe PsO and concomitant csD-MARD use) to the approved dosage regimens of ixekizumab or adalimumab based on the presence/absence of moderateto-severe PsO  [6].
Moderate-to-severe PsO was defined as PASI ≥ 12 with a static Physician Global Assessment ≥ 3 and BSA involvement of ≥ 10% at baseline. A stable dose of csDMARDs, including methotrexate, could be maintained throughout the study if the patient was receiving such treatment at screening. After the week-24 database lock and initial analysis run, nine patients with active PsO and BSA ≥ 3% were found to have been assessed as PASI = 0 at baseline, a medical inconsistency that was resolved using medical judgement. These patients were considered PASI100 responders if PASI = 0 and BSA = 0 at postbaseline visits. SPIRIT-H2H was conducted in accordance with the ethical principles of the Declaration of Helsinki; all patients provided written informed consent and the study protocol was approved by the ethical review board (17/LO/0794) prior to the start of study-related procedures.
Similar analyses were performed at week 52 for CR52 (who simultaneously achieved an ACR50 and PASI100 response at week 52) compared with each of the other three response groups at week 52 (JR52, SR52, and NR52). Adjusted change from baseline in endpoints of interest in each response group was evaluated using an analysis of covariance model that included treatment, moderate-tosevere PsO at baseline, and baseline value as factors. Missing data were imputed using a modified baseline observation carried forward approach. Differences in least squares mean change were evaluated using t-tests. Analyses were performed using SAS Enterprise Guide 7. 15. Sankey diagrams were created to visualise the trajectory of response at week 52.
The current analysis was limited in that it was post hoc. In addition, as only small proportions of patients had dactylitis at baseline, LDI-B response rates should be interpreted with caution. As radiographic progression was not assessed in the SPIRIT-H2H trial, it was not possible to determine potential correlations between simultaneous achievement of ACR50 and PASI100 and inhibition of structural damage. In conclusion, this post hoc analysis of data from the SPIRIT-H2H study showed that the primary endpoint of simultaneous achievement of an ACR50 and PASI100 response at week 24, irrespective of active treatment arm, signalled additional benefits at week 24 across a wide range of efficacy endpoints, including HRQoL, that are important for patients with PsA. Similar findings were seen in week-52 analyses.
Search Strategy We searched MEDLINE, EMBASE, Scopus, and LitCovid data bases from January 1, 2020, to July 19, 2020, by "nervous system" OR "CNS" AND "MR imaging" OR "MR imaging" OR "hypointensities" OR "microbleeds" OR "cerebral microbleeds" OR "microhemorrhages. " Additional studies were identified by manually searching the reference lists of relevant articles. The search strategy is outlined in the Online Supplemental Data in a PRISMA flow chart. This search was conducted the with help of a health science librarian.
Data Extraction Two independent reviewers screened articles by title and abstract for relevance. These studies were then screened for eligibility for inclusion by full-text evaluation. For each included article, 2 independent reviewers extracted data (A. P. , R. C. ). Disagreements were collaboratively resolved within the team. Instructions detailing the type of information to be extracted and how to record, categorize, or code this information were also discussed among team members. The following information was extracted from each article: 1) country, first author, and year of publication; 2) sample characteristics (sample size, age group, and sex distribution); 3) study design; 4) clinical symptoms; 5) reason for brain imaging; 6) type of MR imaging performed; 7) imaging findings; and 8) relevant conclusions to assist article interpretation.
The remaining labels that did not directly match or were broad (eg, basal ganglia, occipitoparietal, temporal, frontal) were localized using the combination of description and MR images available (based on agreement between 2 neuroimaging experts and 1 physician; Online Supplemental Data). White matter bundles from the Illinois Institute of Technology (IIT) Human Brain Atlas were used to label any events located within the white matter. The FSLeyes neuroimaging software from the FMRIB Software Library (https://fsl. fmrib. ox. ac. uk/fsl/fslwiki/FSLeyes) was then used to visualize white matter tracts and gray matter areas from the IIT atlas. Any patient with COVID-19 with nonspecific neuropathologic findings (eg, juxtacortical white matter) or without an accompanying MR image or description was excluded from further analyses.
Neuroimaging Data Visualization The proportion of events number of events Â 100 total cases pertaining to each encoded region within the IIT Desikan-Killiany gray matter atlas and IIT white matter bundles was used for visualization. Gray matter events were visualized using MRIcroGL software (https://www. nitrc. org/projects/mricrogl/). White matter events were visualized using Matlab 2018a (MathWorks) and the toolbox, Version 19b (https://web. conn-toolbox. org/).
Network Diffusion Model of Spread A graph theoretic meta-analysis model was used to test whether the spatial distribution of small neurologic events in the brain can be explained by a spread via the structural connectome of the brain (source code available at: https://github. com/govin2000/ covidspread). NDM was used per previous protocols that identified a spatial pattern of pathology in the brain. 19, 20  The NDM models the hypothetic distribution of pathology in a brain network (given by a connectome C) across time by linear diffusion, given by x t ð Þ ¼ e Àb Ht x 0 , where x 0 is the initial pattern of the neurologic events at t ¼ 0, H is the degree normalized graph Laplacian, and is a diffusivity constant. The unit of the model's diffusion time ðtÞ is assumed to be days (given the likely progression of 5-14 days) for the diffusivity constant of 1 per day.
We acknowledge that some of the neurologic events included in our study may be explained by the healthy ageing process, whereby white matter hyperintensities are correlated with age. 14  Furthermore, IIT tractography data were used for visualization of abnormalities in the white matter. Because only a few labels (eg, corpus callosum) completely match the names of the tracts, the locations are only approximate. Hence, the findings regarding white matter changes, for example, white matter hyperintensities in the centrum semiovale, should be interpreted with caution.
In relation to LT, there is a distinct technical advantage to maintaining a patent main PV in the recipient up to the time of surgery that is associated with improved posttransplant survival. Nonanatomic PV reconstructions during LT add technical difficulty and increase graft ischemic times. These technical complications add risk, and there is inferior survival and more complications in the LT recipient who presents for transplant with PVT. (138, 139)  In the United States, LT regulatory agencies have acknowledged this increased risk by incorporating the presence of pretransplant PVT as a strong independent predictive variable in models of posttransplant survival. (140)  Large transplant database analyses and other case series confirm these findings. (94, 96, 108)  However, it should be noted that these databases lack granularity to determine the size and extent of PVT, and therefore it is unknown if there is a threshold at which outcomes are worse.
Acknowledgment: We thank  Lynee Sanders  and  Audrey Davis-Owino  for their administrative support,  Kristen M. Johnson  for graphic arts and design,  George Ioannou  and  David Goldberg  for their patience and guidance, and the  AASLD Practice Guidelines Committee  for their attention to detail and constant support. Members of the  AASLD Practice Guidelines Committee include George Ioannou , (chair);  Rabab Ali ,  Alfred Sidney Barritt IV ,  James R. Burton ,  Jr. ,  Roniel Cabrera ,  Henry Chang ,  Michael F. Chang ,  Udeme Ekong ,  Ruben Hernaez ,  Binu John ,  Patricia D. Jones ,  Patrick S. Kamath ,  David G. Koch ,  Cynthia Levy ,  Jeff McIntyre ,  Mindie H. Nguyen ,  Mary E. M. Rinella  (board liaison),  Lopa Mishra , (board liaison),  Anjana A. Pillai ,  Daniel S. Pratt ,  David J.
PVT prevalence and risk factors: patients with cirrhosis Determining the incidence and prevalence of PVT is difficult due to the heterogeneity of risk factors in the population and the lack of a universal classification system. As a result, the reported prevalence and incidence of PVT vary widely. The most studied cirrhosis population with regard to PVT is LT candidates. One report based on 849 patients with cirrhosis who underwent LT with well-defined explant thrombosis classification described a prevalence of 9% with either partial or complete obstruction of the main PV. (94) Another study from Japan showed autopsy PVT prevalence of 0. 05% in patients without cirrhosis and 6. 59% in patients with cirrhosis. (104) Recent reports, including national databases of hospital discharge and transplant registries, have listed prevalence rates in patients with cirrhosis between 1.
Patients and data collection All adult patients with newly diagnosed PMBL treated in France and Belgium by participating LYSA centers from 1 January 2007 to 31 December 2017, were identified from local databases. The inclusion criteria were as follows: first-line ACVBP or CHOP plus anti-CD20, available pretreatment (baseline) PET, and patients' nonopposition statement. PMBL diagnosis was made locally in each center and based on typical clinical presentation and histologic criteria described in the 2008 and 2016 World Health Organization classification,  1, 20  with the support of the French Lymphopath 21 network after 2009. Data were retrospectively collected from medical records in all centers. "Bulky" was defined as disease $10 cm in axial diameter. Primary refractory disease was defined as lymphoma progression during treatment or within 3 months of treatment completion.
Patients' characteristics A total of 313 patients were enrolled from 25 LYSA centers. The patients' characteristics are listed in Table  1. The median age at diagnosis was 32 (18-88) years; the majority of patients were female (n 5 190 [60. 7%]) and presented at diagnosis with a good performance status (Eastern Cooperative Oncology Group performance status 0-1, 81. 8%), Ann Arbor stage I to II (57. 5%), elevated lactate dehydrogenase (81. 8%), bulky disease (58. 5%), international prognostic index (IPI) 1 to 2 (60. 7%), and CNS IPI 2 to 3 (36. 4%). No patient had CNS involvement at diagnosis. Sixteen (5. 1%) patients presented with thrombotic events related to tumor mass before treatment. Mediastinal masses were reported in 278 (96%, data not available 5 23) patients and were the main biopsy site for diagnosis.
Toxicity Safety data were retrospectively collected for 313 (100%) patients. All-grade treatment-related adverse events were similar among the groups, except for an excess of febrile neutropenia (5. 3% vs 5. 3% vs 24. 4%; P ,. 001) and mucositis (1. 8% vs 3. 9% vs 22. 8%; P ,. 001) (supplemental Table  8 ) in the R-ACVBP group. Two toxic deaths were observed (R-CHOP21, n 5 1; R-ACVBP, n 5 1). A very low rate (n 5 7 [2. 2%]) of cardiac events was reported (including 2 episodes of chest pain and 1 of atrial fibrillation), with only 3 events (1%) related to acute anthracycline toxicity (cardiomyopathy with the development of heart failure). Secondary malignancies (SM) appeared in 7 (2. 2%) patients (R-CHOP21, n 5 2; R-ACVBP, n 5 5 [2. 8%]), including 3 cases of acute myeloid leukemia (R-ACVBP group), 1 Ewing sarcoma, 1 thyroid papillary microcarcinoma, 1 carcinoma in situ of the uterine cervix, and 1 squamous cell carcinoma.
The results of the IELSG-37 (#NCT01599559) study are awaited to provide results based on a randomized study and may conclusively settle the debate. 47 9] [50]  In this situation, retreatment with salvage high-dose chemotherapy followed by ASCT is the standard of care. 19, 51 Nevertheless, relapsed PMBL is often chemoresistant, and the patients will either not actually undergo ASCT or will relapse early after ASCT with a poor prognosis (2-year PFS2, 30%). PMBL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 ligands; therefore, pembrolizumab, an anti-programmed cell death-1 checkpoint antibody, was tested as a single agent  52  in patients with PMBL relapsing after ASCT, with good results and a manageable safety profile. In addition, a combination of checkpoint inhibitors and brentuximab vedotin  53  has been reported as promising in third-line or more therapy.
Our study has several limitations that should be highlighted. First, it was a retrospective study that inevitably involved missing data. More centers from the former Groupe d'Etude des Lymphomes de l'Adulte (GELA), who are used to R-ACVBP, participated in this study, in contrast to the former Groupe Ouest Est des Leuc emies et Autres Maladies du Sang (GOELAMS) centers, who are used to R-CHOP and who participated less; this may represent a selection bias. We have no information on the factors that motivated the centers to choose R-CHOP over R-ACVBP. The decision was left to each investigator and mainly corresponded to a center's habit. Patients' comorbidities were taken into account in addition to patients' age, but comorbidity data were not collected. Regarding other limitations, we do not have sufficient data on physicians' motivations for their choice of consolidative options (eg, ASCT, CRT, SCC) according to iPET results, for several reasons: (1)  In addition, our study does not have enough power to explore the results of the 3 regimens in the IPI 0 subgroup.
iPET was performed at different times during the treatment course in a heterogeneous way; (2) serial PET2/PET4 data were missing in the R-CHOP groups; (3) variable methods were used for interpreting PET responses; (4) local treatment guidelines have evolved over time; and (5) no data are available on whether biopsies were performed by the centers based on DS4 at EoT. Our cohort may not be representative of the overall PMBL population because baseline PET was mandatory for inclusion. Because PMBL is sometimes diagnosed in an emergency context, and patients may receive treatment with no baseline PET, we may have possibly missed the sickest patients. Furthermore, no dedicated PMBL registry exists in LYSA centers. The identification of PMBL patients in this study has called on local databases, and selection biases are inevitable.
Acknowledgments The authors thank the patients and their families; the reviewers at the LYSA, notably  Thierry Lamy  and  Herv e Ghesqui  eres; the LYSARC; and all of the investigators in the LYSA centers. They also thank  Julie Libraire , clinical data manager at the  Clinical Research Unit, Centre Henri Becquerel , and  Doriane Richard ,  CRA manager , for support in this study. The authors thank  Arthur Dumouchel  and  Pierrick Gouel  for imaging data management in this study. This work was supported by grants from the  Centre Henri Becquerel  and the  Ligue Contre le Cancer  ( Comit e de la Manche ).
We therefore conducted a systematic literature search to evaluate the existing data on bipolar disorder and marital issues, with a special focus on the help and support that could be provided by mental health professionals in this regard. For the review, electronic searches of articles published between 1 January 1970 and 31 March 2021 were done using various search engines such as PubMed, Google Scholar, and Science direct. The search terms used in various permutations and combinations included bipolar disorder, marital relationship, couple relationship, couple functioning, partner, spouse, children and couple therapy. We excluded articles on caregivers' issues, in which a proportion of caregivers were partners, but no separate analysis was done to compare the caregivers' issues of partners and other caregivers.
N-BPs are several orders of magnitude more potent than nN-BPs at inhibiting bone resorption in vivo  [10, 11]. The mevalonate pathway inhibited by N-BPs has a central role in cholesterol (Chol) biosynthesis and in glucose homeostasis and is a well-known molecular target also for statins, the first-choice treatment for dyslipidemia  [12]. In consideration of the above, the objective of this retrospective cohort study was to evaluate if BP treatment affects lipid and glucose blood levels in patients with PDB treated with Zol or Clo. We also analyzed data collected from patients with complicated Op treated with Zol.
Materials and Methods This retrospective cohort study was performed analyzing the medical records of all consecutive Caucasian patients with PDB [International Classification of Diseases (ICD)-9 code 731. 0] and with complicated Op (ICD9 codes 73310-9) referring from January 01, 2009, to December 31, 2018, at the Units of Bone and Mineral Disorders of Siena and Naples, two main national centers for the diagnosis and treatment of MBDs which used a unique approach for clinical classification and management of MBDs and their comorbidities  [13, 14]. On their first admission, all patients were informed that (i) their personal data, collected as part of administrative management and hospital care, could be used for health research purposes, under the responsibility of the Federico II University of Naples and of Siena University; (ii) they could withdraw their consent to the use of personal data without providing further explanation at any time and without medical assistance being affected.
This, in the form of written informed consent, was obtained from each patient or subject involved in this study. Data collection was performed from July 01, 2019, to December 31, 2019. The PDB and Op diagnoses were based on published criteria  [9, 15]. Only medical records of patients treated with Zol 5 mg intravenously (i. v. ) or Clo 1500 mg i. v. were selected for this study  [16, 17] , to compare N-BP to nN-BP regimens. The BP treatment was administered after supplementation of cholecalciferol and/or calcium in all cases (http://www. agenz iafar maco. gov. it/conte nt/nota-79)  [18]. Cholecalciferol supplementation and an adequate calcium dietary intake were also prescribed after BP treatment (http://www. agenz iafar maco. gov. it/conte nt/ nota-79)  [18, 19]. According to a pre-established collection schedule, the following data were extracted from selected medical records: age, sex, body mass index (BMI), data of infusion, type of drug, glycaemia (sGlu), serum calcium (sCa), total Chol (tChol), low-density lipoproteins-Chol (LDL), high-density lipoprotein-Chol (HDL), triglycerides (TG), 25OH-vitamin D (25OHD), total alkaline phosphatase (ALP), and creatinine (sCrea) levels.
Statistical Analysis All statistical analyses were performed using the IBM SPSS Statistics, version 23 (International Business Machines Corporation, Inc. , Armonk, NY, USA). Data are expressed as means ± standard deviation for continuous variables and as absolute; percentage values for discrete variables. Contingency table χ 2 tests and analysis of variance (with Bonferroni correction for multiple comparisons) were used to test for between-group differences in non-parametric and parametric variables, respectively. Differences from baseline after BP treatment were estimated using the Student's t test or the Wilcoxon test for variables with normal or not-normal distribution, respectively. A p value < 0. 05 was considered statistically significant.
Molecular Docking with IL-13 A docking study was conducted by using SOFTWARE BIOVIA DISCOVERY STUDIO 19. 0. Embelin and dexamethasone were docked with protein PDB ID 3L5X (crystal structure of IL-13 complexed with H2L6 FAB). The molecular docking was run by a CDOCKER automated flexible docking protocol. The study was conducted Subsequently, the structures of embelin and dexamethasone were constructed using ChemBioDrawUtra 12. 0. Then, minimization of energy of each ligand pose was completed by CHARMm force field using CDOCKER protocol 10. The highest scored complex for each binding site was calculated as CDOCKER energy (kcal/mol) and was used for analysis. Other parameters were also observed, including the binding, ligand, protein and complexing energies of both the ligands. In this study, 3D conformers of embelin and dexamethasone were docked with the active site of the target protein 3L5X (IL-13).
Molecular Docking of Embelin with IL-13 (3L5X) IL-13 plays a major role in causing inflammation during an asthmatic attack by bronchial constriction. Hence, molecular docking was performed to predict the interactive mode of embelin and dexamethasone to reveal novel information of the receptor protein and the ligand structure. Molecular docking study of the active sites for embelin and dexamethasone with 3L5X (Figure  8 ) was performed using a Discovery Studio 4. 5 ACCERLYS software to assess and compare their binding scores and affinities with the co-crystallized ligand. Embelin forms two conventional hydrogen bonding interaction at 3L5X active site (Figure  8 ). The oxygen atom of the hydroxy group in embelin allows hydrogen bonding with hydrogen atom of ARG L: 61 (O-H-ARG L: 61). On the other hand, the hydrogen atom of the hydroxyl group of embelin forms a hydrogen bonding interaction with the hydrogen atom of GLU L: 79 (OH-O-GLU L:79).